Gardasil to be a $10 billion earner if approved for male patients: analyst

Share this article:

Merck's human papillomavirus vaccine Gardasil could become a blockbuster 10 times over if the drugmaker can win approval for use of the treatment in men.

With Gardasil use rising faster than that of any new vaccine, administering it to boys and young men as well as girls could push annual sales potential above $10 billion, according to Lisa Kelly, an analyst at Wood Mackenzie Consultants Ltd. in Edinburgh, Scotland.

If Kelly's estimates are correct, it would make Gardasil Merck's best-selling product, far bypassing Singulair which had sales of $3 billion in 2006.

Merck is currently conducting studies to prove that Gardasil can prevent the spread of HPV infections in men. 

Meanwhile analysts estimate that Gardasil may generate as much as $1.4 billion in its first full year on the market as regulators across the globe endorse the vaccine as a means to prevent cervical cancer caused by the sexually transmitted human papillomavirus.

Share this article:
close

Next Article in News

Email Newsletters

More in News

Sanofi expands Gaucher disease portfolio

Sanofi expands Gaucher disease portfolio

The oral medication Cerdelga joins Cerezyme in its Fabry disease arsenal. Sanofi expects the drug will be priced "on par" with Cerezyme, which goes for around $300,000 a year in ...

Amicus seeks to upset Fabry market

Amicus seeks to upset Fabry market

Phase-III tests indicate patients may be able to switch from injectable enzyme-replacement therapies, like Fabrazyme, to the firm's oral drug.

Five things for pharma marketers to know: Wednesday, August 20

Five things for pharma marketers to know: Wednesday, ...

Novartis explores the virtual care space, a court has dismissed a lawsuit against IPAB, Doctors Without Borders calls the Ebola outbreak "a complete disaster" and Pfizer becomes the first pharma ...